The United European Gastroenterology (UEG) week is taking place from the 19th to the 23rd October in Barcelona, and the New Deal project team will attend it! We will hold a Common Interest Group meeting called “Unmet therapeutic needs in IBD – how new targeted medicine could help” the 22nd of October at 18:00h. Recent therapeutic development programs in the … Read More
October New Deal Reads
1. Nanocarrier-based systems for targeted and site specific therapeutic delivery. Majumber et al. 2019. Advanced Drug Delivery Reviews. One of the major problems of the current IBD therapies is that they produce side effects when they are delivered in a systemic way like oral administration. Thus, there is a need to develop targeted delivery strategies that affect only the body … Read More
Living with IBD: lost in diagnosis
Digestive problems, bloating intestine, diarrhoea… Gastrointestinal diseases are varied but, at least by looking at their symptoms, almost every one of them can look the same to the unexperienced eye. One of the first challenges for doctors when it comes to these diseases is getting an accurate diagnosis. Because, although they may have similar symptoms, Irritable Bowel Syndrome (IBS) is … Read More
New Deal News: New publication from HIPS-HZI
On the way to their target, our nanoparticles loaded with siRNA have to cross the intestinal mucosa and thus, understanding the properties of the mucus & its surrogates is key to improve drug-delivery! Our partners from the Helmholtz Zentrum HIPS just published this paper about it! Here you will find all the news about our team and the progress of … Read More
A molecule with a destiny: modelling drug delivery in IBD
Since a drug enters our body, it will complete a journey inside it that is full of difficulties. For example, when we take an aspirin, the analgesic molecules have to go all the way from the mouth to the pain location, facing, among other hazards, the harsh conditions of the stomach. Regardless of how the drug is administered, it must … Read More
July New Deal Reads
siRNA Targeting and Treatment of Gastrointestinal Diseases. Chevalier R. 2019, Clinical and Translational Science siRNA is considered as an effective way to treat some gastrointestinal diseases such as inflammatory bowel disease. This therapy can target with accuracy genes that contribute to the excessive inflammation found in this illness. Nevertheless, the delivery of siRNA to the cells of interest remains a … Read More
Uncovering IBD: communicating chronic diseases
An important part of the current scientific research is focused on the combat of diseases that nowadays are uncurable. This is the case of New Deal project, in which researchers from different disciplines are working together to develop a treatment for inflammatory bowel disease (IBD). One way to make people benefit from the outcomes of disease research is to let … Read More
June New Deal Reads
X. Sun, S. Dong, X. Li, et al. Delivery of siRNA using folate receptor-targeted pH-sensitive polymeric nanoparticles for rheumatoid arthritis therapy. 2019. Nanomedicine: Nanotechnology, Biology, and Medicine siRNA technology is a promising therapy for autoimmune diseases like inflammatory bowel disease (IBD) or rheumatoid arthritis, as it can silence the expression of genes responsible for the inflammation. However, the delivery of … Read More
Silencing IBD: when a tiny molecule can make a great difference.
Take a quick look on your body. We are a combination of one hundred thousand billion cells. Inside each one of them, we can find all our DNA that holds more than twenty thousand genes. DNA remains in the cell nucleus and, when its information is needed, it doesn’t leave it. Instead, it is transcribed in a different kind of … Read More
World IBD Day 2019
Over ten million people worldwide live with IBD, a disease that goes unnoticed by most of the people around them. To increase its visibility today we celebrate world IBD day. Under the motto “Making the invisible visible” over 50 countries are joining this initiative to show support to all the IBD warriors out there and to show to the society … Read More
May New Deal Reads
A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function. De Vries L. C. S et al. Inflammatory Bowel Disease. 25 (4) 2019. Janus kinases (JAKs) are involved in the intestinal inflammation found in IBD. A common treatment for this disease is tofacitinib, a drug that inhibits different JAKs. Although this therapy is effective, it doesn’t target only … Read More
Living with IBD: treatments
If you have reached this post, maybe you have been recently diagnosed with inflammatory bowel disease or know someone who has been. They are very common: over two million people in Europe live with an IBD, being Crohn’s disease and Ulcerative colitis the most widely spread. The principal characteristic of IBD conditions is the swelling of the digestive tract, which … Read More
April New Deal Reads
1. Targeting JAK-STAT signal transduction in IBD. Soendergaard C. et al. Pharmacology & Therapeutics 192(2018): 100-111 Antibody-based biological drugs were a significant advance for IBD treatments, but unfortunately a high percent of patients doesn’t respond well to this therapy highlighting the need for alternative therapies. Recent studies have shown the great potential of JAK inhibitors to face this unmet medical … Read More
Keep Calm and research on! Consortium meeting in London
Six months passed by since our last meeting in Barcelona so it was time for another face to face meeting for the members of the New Deal consortium. This time in London and hosted by our partners from BOYDS we celebrated our third Annual Meeting to discuss about our progress and define the future steps of our project. Moreover we … Read More
February New Deal Reads
In New Deal Reads we have prepared for you a selection of relevant papers in the field of IBD and nanotechnology so you can stay tuned with the new advances: 1. Local delivery of macromolecules to treat diseases associated with the colon, Bak A, .Ashford M, Brayden D.J. Journal: Advanced Drug Delivery Reviews in December 2018 The local delivery of … Read More
NEW DEAL was rewarded at Mayoly’s Forum
The Mayoly Management Forum took place from the 5th to the 8th of February, in Valence. The event gathered all the managers from Mayoly and at this occasion the New Deal project was presented. A new nanotherapy research for inflammatory bowel diseases The goal of the project NEW DEAL is to design and validate a new targeted therapy against inflammatory bowel diseases (IBDs). This … Read More
New EU project develops a highly selective and local therapy for Inflammatory Bowel Diseases
The innovations introduced by NEW DEAL strengthen the leadership of Europe in the field of advanced therapies and in particular, in nanotherapies. An alternative therapy for inflamatory bowel diseases (IBDs) The goal of the new European project NEW DEAL is to design and validate a new targeted therapy against inflammatory bowel diseases (IBDs). This therapy is aimed at treating patients … Read More
